Annual Report

Overview

The report highlights Kazia's FDA Fast Track Designation for paxalisib in solid-tumour brain metastases, alongside continued clinical pipeline development. It reports that the compassionate program treated over 40 patients in seven countries since 2018. Governance disclosures include the appointment of the company's first female board member in 2023.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 30 June 2023
Publication date: 31 August 2023
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services